Apexium Financial LP Invests $2.16 Million in Illumina, Inc. (NASDAQ:ILMN)

Apexium Financial LP bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,500 shares of the life sciences company's stock, valued at approximately $2,158,000.

Several other institutional investors have also recently made changes to their positions in ILMN. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Illumina in the 3rd quarter valued at $30,000. VisionPoint Advisory Group LLC grew its position in shares of Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company's stock valued at $34,000 after purchasing an additional 193 shares during the period. Wetzel Investment Advisors Inc. purchased a new stake in Illumina in the fourth quarter valued at approximately $37,000. Gradient Investments LLC grew its position in Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company's stock valued at $40,000 after acquiring an additional 225 shares during the period. Finally, North Star Investment Management Corp. grew its holdings in shares of Illumina by 183.0% during the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company's stock worth $42,000 after purchasing an additional 194 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Down 0.5 %

Shares of NASDAQ ILMN traded down $0.55 during mid-day trading on Thursday, reaching $114.46. 996,919 shares of the company traded hands, compared to its average volume of 1,722,418. The company's fifty day moving average is $126.07 and its two-hundred day moving average is $126.80. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $213.91. The stock has a market cap of $18.23 billion, a PE ratio of -14.05 and a beta of 1.20.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business's quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 EPS. On average, analysts expect that Illumina, Inc. will post 0.87 earnings per share for the current year.

Analysts Set New Price Targets

ILMN has been the subject of a number of research reports. Robert W. Baird upped their price target on shares of Illumina from $125.00 to $128.00 and gave the stock a "neutral" rating in a research report on Friday, May 3rd. StockNews.com raised shares of Illumina from a "hold" rating to a "buy" rating in a research report on Saturday, May 11th. Barclays raised their price target on shares of Illumina from $85.00 to $100.00 and gave the company an "underweight" rating in a report on Wednesday, April 10th. Royal Bank of Canada reiterated an "outperform" rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Finally, OTR Global reiterated a "mixed" rating on shares of Illumina in a research note on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, Illumina has an average rating of "Hold" and an average target price of $164.65.

Insider Buying and Selling

In other news, CEO Jacob Thaysen bought 7,330 shares of the company's stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at approximately $2,010,544.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.17% of the stock is owned by company insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.